Deena Graham, MD
Medical Oncology · Hackensack, NJNPI 1790716926
Payments from drug & device makers
Across 505 payments — averaging $5351.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1.3M
- Merck$561K
- Karyopharm Therapeutics Inc.$307K
- Seagen Inc.$267K
- AstraZeneca$106K
- Sanofi US Services Inc.$58K
- plus $80K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 84 | $1,323,073 |
| Merck | 65 | $560,881 |
| Karyopharm Therapeutics Inc. | 23 | $306,622 |
| Seagen Inc. | 71 | $267,106 |
| AstraZeneca | 28 | $106,326 |
| Sanofi US Services Inc. | 16 | $58,241 |
| Jazz Pharmaceuticals Inc. | 4 | $32,580 |
| Genentech, Inc. | 3 | $29,750 |
| Macrogenics, Inc. | 5 | $7,967 |
| Eisai Inc. | 12 | $4,077 |
| Eli Lilly | 2 | $2,282 |
| Novartis | 81 | $1,399 |
| Daiichi Sankyo Inc. | 39 | $799 |
| Gilead | 21 | $370 |
| GSK | 18 | $318 |
| Astrazeneca UK Limited | 1 | $135 |
| AbbVie | 6 | $103 |
| Mirati Therapeutics, Inc. | 5 | $95 |
| Fennec Pharmaceuticals, Inc. | 2 | $53 |
| Genentech USA, Inc. | 3 | $44 |
| Foundation Medicine, Inc. | 1 | $44 |
| Johnson & Johnson(2 entities) | 3 | $42 |
| Apellis Pharmaceuticals, Inc. | 2 | $35 |
| Amgen | 2 | $29 |
| Novo Nordisk | 1 | $25 |
| Stemline Therapeutics Inc. | 1 | $24 |
| Rigel Pharmaceuticals, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $19 |
| Taiho Oncology, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Pharmacosmos Therapeutics Inc. | 1 | $14 |
| Heron Therapeutics, Inc. | 1 | $14 |
How this compares
$2,702,522 in reported general payments places this provider in the 85th percentile of 112 medical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Hackensack
- Martin GutierrezHackensack$41.8M
- James McCloskeyHackensack$17.1M
- Lori LeslieHackensack$11.9M
- Tatyana FeldmanHackensack$8.4M
- David SiegelHackensack$6.9M
- Noa BiranHackensack$5.8M
- Andrew PecoraHackensack$4.5M
- Robert AlterHackensack$4.5M
- Jamie KoprivnikarHackensack$3.8M
- David VesoleHackensack$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.